Lori M. Waldron is Co-Chair of the Sills Cummis & Gross Life Sciences Practice Group. Her practice focuses on the representation of both emerging growth and well-established public and private companies in sophisticated business transactions, with a particular emphasis on the life sciences and biotech industries. Ms. Waldron has extensive experience representing clients through all phases of their business cycles and advising them how to best take advantage of varying business opportunities, whether arising in the ordinary course of business or as an extraordinary matter. Her regular practice includes counseling her clients in connection with start-up matters (including formation issues, corporate debt and equity structure, shareholder arrangements and officer/director/employee compensation issues), angel and venture capital financings, private equity and debt investments, joint ventures and other strategic and collaborative alliances, and manufacturing and supply arrangements. Ms. Waldron also advises her clients in connection with a wide variety of complex business purchases, combinations and divestitures (including mergers, acquisitions, stock and asset sales, spin-offs, license agreements and sublicense arrangements) and general corporate matters.